https://www.selleckchem.com/products/CP-690550.html Stent placement for basilar artery (BA) stenosis remains a technical and clinical challenge. This retrospective study introduces the experience with the Apollo balloon-expandable stent (BES) for patients with symptomatic BA stenosis in a single centre in China. Sixty one patients who had undergone intervention for severe symptomatic BA stenosis between May 2012 and September 2018 were enrolled in this study. All patients underwent angioplasty and stenting with an Apollo BES and were followed-up continuously. The technical success rate was 100%. During the procedure, there was no vessel rupture or dissection. Two patients died due to perforator occlusion. One patient developed vasospasm with no symptoms. The rate of complications during the procedure was 4.91% (3/61). BA stent-related stroke or death rates were 4.9% at 30 days (3/61), 6.6% at 3 months (4/61), and 6.6% (4/61) at 6 months. One patient had stent occlusion at 6 months with no symptoms. Restenosis was found in five patients with degrees of restenosis greater than ≥ 50% without any symptoms. In this study, the Apollo BES appeared to be feasible for BA stenosis. Our experience may be valuable for reducing the number of complications. However, further study is needed.Antithrombotic therapy is a critical component of the management of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and improve myocardial salvage. High residual platelet reactivity (HRPR) has been reported up to 4 or 6 h after loading dose of prasugrel or ticagrelor; therefore, multiple alternative strategies, including crushed or chewed oral tables or intravenous agents, have been investigated to provide a more rapid and sustained inhibition of platelet function and bridge the initial treatment gap. The FABOLUS FASTER is the firs